Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-22
2005-02-22
Brumback, Brenda (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S009100, C530S317000, C530S323000
Reexamination Certificate
active
06858585
ABSTRACT:
Cyclic depsipeptides represented by the formulawherein:R is a straight or branched alkyl group of 5-20 carbon atoms or a straight or branched alkoxymethyl group of 5-15-carbon atoms; A, B, D, E and F independently each other are alanine, valine, leucine, isoleucine, phenylalanine, etc.; W and Z independently each other are aspartic acid, asparagine, glutamic acid or glutamine; and m and n independently each other is 0 or 1, or pharmacologically acceptable salts thereof. The present compounds are prepared according to a method conventionally used in peptide synthesis. The present compounds are useful as an agent for promoting the production of apolipoprotein E, a therapeutic agent for neurologic damages, a therapeutic agent for dementia, an agent for inhibiting the production of apolipoprotein B, an agent for promoting the production of apolipoprotein A1 or a therapeutic agent for hyperlipemia.
REFERENCES:
patent: 5801143 (1998-09-01), Hiramoto et al.
patent: 6316406 (2001-11-01), Yanai et al.
patent: 7-291993 (1995-11-01), None
patent: WO 9532990 (1995-12-01), None
(cont. X) Oct. 2002. Abstract Only.*
Okamoto et al. ‘Treatment of Vacular Dementia’, Ann. NY Acad. Sci. p 507-512. 2002.*
Pinderhuges et al. Evidence Based Approach to Management of Fever in Patients with End Stage Dementia. Journal of Palliative Medicine, Jun. 2003, vol. 6, Iss. 3, p351. Abstract Only.*
Patel Shirish V. Pharmacotherapy of Ognitive Impariment in Alzheimer's Disease: A Review J. of geriatric Physchiatry and Neurology, vol. 8, pp. 81-95. Apr. 1995.*
Fukuyama et al. ‘Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease’ European Neurology, vol. 43, 3, p. 161-169. Apr. 2000.*
File Medline on STN. An No. 97230053. Urabe et al. ‘Effects of Estrogen Replacement Therapy on Hepatic Triglyceride Lipase, Lipoprotein Lipase and Lipids Including Apolipoprotein e In Climacteric and Elderly Women.’ Endocrinology Journal, vol. 43, No. (V con.t)—6, pp. 737-742. Dec. 1996 Abstract Only.*
File Medline on STN. An No. 2002690364 Auld et al. ‘Alzheimer's Disease and the Basal Forebrain Cholinergic System: Relations to Beta-Amyloid Peptides, Cognition, and Treatment Strategies.’ Progress in Neurobiology, vol. 68, No. 3, p. 209-245.*
Jacqueline, A, et al. Halobacillin: A Cytotoxic Cyclic Acylpeptide of the Iturin Class Produced by a Marine Bacillus. Tetrahedron Letters, 1994, vol. 35, No. 31, (pp. 5571-5574).
Harrigan, G.G. et al., Kailuins A-D, New Cyclic Acyldepsipeptides from Cultures of a Marine-Derived Bacterium. Tetrahedron, Feb. 1997, vol. 53, No. 5 (pp. 1577-1582).
Proc. Natl. Acad. Sci. USA, “Expression of apolipoprotein E during nerve degeneration and regeneration”, Michael J. Ignatius, et al. vol. 83, (pp. 1125-1129).
Hiramoto Shigeru
Kawamura Koji
Kinoshita Nobuhiro
Oshida Norio
Shingai Akiko
Brumback Brenda
Gupta Anish
Nisshin Seifun Group Inc.
LandOfFree
Cyclic depsipeptides and drugs containing the same as the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic depsipeptides and drugs containing the same as the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic depsipeptides and drugs containing the same as the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3494836